Update in the treatment of paediatric ulcerative colitis

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 14, 2006, Pages 1907-1918

  Greifer, Melanie K ^a   Markowitz, James F ^a  

^a SCHNEIDER CHILDREN'S HOSPITAL   (United States)

Author keywords

Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; ALICAFORSEN; ATL 2502; BASILIXIMAB; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CALCINEURIN INHIBITOR; CORTICOSTEROID; DACLIZUMAB; DIPHENHYDRAMINE; EPIDERMAL GROWTH FACTOR; HYDROCORTISONE; IMMUNOMODULATING AGENT; INFLIXIMAB; MESALAZINE; METHOTREXATE; MLN 02; MONOCLONAL ANTIBODY; NATALIZUMAB; NICOX 1015; PARACETAMOL; PLACEBO; PREBIOTIC AGENT; PREDNISOLONE DERIVATIVE; PROBIOTIC AGENT; REBAMIPIDE; ROFLEPONIDE; STEROID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VISILIZUMAB;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ACNE; ANTIINFLAMMATORY ACTIVITY; APHERESIS; ARTHRALGIA; ARTHRITIS; AVASCULAR NECROSIS; BIOLOGICAL THERAPY; BODY WEIGHT DISORDER; BONE MARROW SUPPRESSION; CANCER RISK; CATARACT; CEREBRAL BLINDNESS; CHEST TIGHTNESS; CHILD; CHILDHOOD DISEASE; CHILL; CLINICAL TRIAL; COLORECTAL CANCER; CROHN DISEASE; CYTOKINE PRODUCTION; DIABETES MELLITUS; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG FORMULATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; FIRST PASS EFFECT; GLAUCOMA; GROWTH RETARDATION; HIRSUTISM; HUMAN; HYPERTRICHOSIS; HYPOTENSION; LEUKOPENIA; LIVER TOXICITY; MALAISE; MOOD DISORDER; MOON FACE; MORBIDITY; NAUSEA; NEPHROTOXICITY; OSTEOPOROSIS; PANCREATITIS; PNEUMOCYSTOSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REVIEW; RISK ASSESSMENT; SEIZURE; STRIA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; VOMITING; WEIGHT GAIN;

ADRENAL CORTEX HORMONES; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHILD; CLINICAL TRIALS; COLITIS, ULCERATIVE; EXPERT TESTIMONY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PEDIATRICS; PROBIOTICS;

EID: 33749343555     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.14.1907     Document Type: Review

References (99)

1. KUGATHASAN S, JUDD RH, HOFFMANN RG et al.: Wisconsin Pediatric Inflammatory Bowel Disease Alliance. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a state wide population-based study. J. Pediatr. (2003) 143:525-531.
2. HILDEBRAND H, FINKEL Y, GRAHNQUIST L, LINDHOM J, EKBOM A, ASKLING J: Changing pattern of paediatric inflammatory bowel disease in northern Stockholm 1990 - 2001. Gut (2003) 52:1432-1434.
3. WEWER V, HESSELFELDT P, QVIST N, HUSBY S, PAERREGAARD A: J-Pouch ileoanal anastomosis in children and adolsescents with ulcerative colitis: functional outcome, satisfaction and impact on social life. J. Pediatr. Gastroenterol. Nutr. (2005) 40:189-193.
4. BREMNER AR, GRIFFITHS DM, BEATTIE RM: Current therapy of ulcerative colitis in children. Expert Opin. Pharmacother (2004) 5:37-53.
5. BOUMPAS DR, PALLOGIANNI F, ANASTASSIOU ED, BALOW JE: Glucocorticosteroid action on the immune system: molecular and cellular aspects. Clin. Exp. Rheumatol. (1991) 9:413-423.
6. BARNES PG, ADCOCK I: Anti-inflammatory actions of steroids: molecular mechanisms. Trends Pharmacol. Sci. (2003) 14:436-441.
7. BEATTIE RM, NICHOLLS SW, DOMIZIO P et al.: Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. (1996) 22:373-379
8. HYAMS J, MARKOWITZ J, LERER T et al.: The natural history of corticosteroid therapy for ulcerative colitis in children. Clin Gastroenterol. Hepatol. In Press.
9. UCHIDA K, ARAKI T, TOIYAMA Y et al.: Preoperative steroid-related complications in Japanese pediatric patients with ulcerative colitis. Dis. Colon Rectum (2006) 49:74-79.
10. LEVINE A, WEIZMAN Z, BROIDE E et al.: A comparison of budesonide and prednisone for the treatment of active pediatric Crohn's disease. J. Pediatr. Gastroenterol. Nutr. (2003) 36:248-252.
11. RIZZELLO F, GIONCHETTI P, D'ARIENZO A et al.: Oral beclometasone diproprionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Aliment. Pharmacol. Ther. (2002) 16:1109-1116.
12. NIKOLAUS S, FOLSON U, SCHREIBER S: Immunopharmacology of 5-aminosalicylates and of glucocorticoids in the therapy of inflammatory bowel disease. Hepatogastroenterology (2000) 47:71-82.
13. MARAKHOUSKI Y, FIXA B, HOLOMAN J et al.: A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis. Aliment. Pharmacol. Ther. (2005) 21:133-140.
14. PRANTERA C, VISCIDO A, BIANCONE L, FRANCAVILLA A, GIGLIO L, CAMPIERI M: A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflamm. Bowel Dis. (2005) 11:421-427.
15. WIERSMA H, ESCHER JC, DILGER K et al.: Pharmacokinetics of mesalazine pellets in children with inflammatory bowel disease. Inflamm. Bowel Dis. (2004) 10:626-631.
16. SUTHERLAND L, ROTH D, BECK P, MAY G, MAKIYAMA K: Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis (Cochrane Review). In: The Cochrane Library, Issue 2. John Wiley, Chicester, UK (2004).
17. SUTHERLAND L, MACDONALD JK: Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis (Cochrane Review). In: The Cochrane Library, Issue 2. John Wiley, Chicester, UK (2004).
18. VAN STAAT P, CARD T, LOGAN RF, LEUFKENS HG: 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut (2005) 54:1573-1578.
19. HANAUER SB, SANDBORN WJ, KORNBLUTH A et al.: Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am. J. Gastroenterol. (2005) 100:2478-2485.
20. MARTEAU P, PROBERT CS, LINDGREN S et al.: Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomized, double blind, placebo controlled study. Gut (2005) 54:960-965.
21. TIEDE I, FRITZ G, STRAND S et al.: CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J. Clin. Invest. (2003) 111:1133-1145
22. MARKOWITZ J, GRANCHER K, KOHN N, DAUM F: Immunomodulatory therapy for pediatric inflammatory bowel disease: changing patterns of use, 1990-2000. Am. J. Gastroenterol. (2002) 97:928-932.
23. DUBINSKY MC: Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastro Hepatol (2004) 2:731-743.
24. ARDIZZONE S, MACONI G, RUSSO A, IMBESI V, COLOMBO E, BIANCHI PORRO G: Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut (2006) 55:47-53.
25. KADER HA, MASCARENHAS MR, PICCOLI DA, STOUFFER NO, BALDASSANO RN: Experiences with 6-mercaptopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. (1999) 28:54-58.
26. KIRSCHNER BS: Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology (1998) 115:813-821.
27. SEIDMAN EG: Clinical use and practical application of TPMT enzyme and 6-mercaptopurine metabolite monitoring in inflammatory bowel disease. Rev. Gastroenterol. Disord (2003) 3:S30-S38.
28. KANDIEL A, FRASER AG, KORELITZ BI, BRENSINGER C, LEWIS JD: Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut (2005) 54:1121-1125.
29. SHIBOLET O, REGUSHEVSKAYA E, BREZIS M, SOARES-WEISER K: Cyclosporin A for induction of remission in severe ulcerative colitis (Cochrane Review). In: The Cochrane Library Issue 1. John Wiley, Chicester, UK (2005).
30. PHAM CQ, EFROS CB, BERARDI RR: Cyclosporine for severe ulcerative colitis. Ann. Pharmacother. (2006) 40:96-101.
31. TREEM WR, COHEN J, DAVIS PM, JUSTINICH CJ, HYAMS JS: Cyclosporin for the treatment of fulminant ulcerative colitis in children. Immediate response, long-term results and impact on surgery. Dis. Colon Rectum (1995) 38:474-479.
32. ROSENCRANTZ R, MOON A, RAYNES H, SPIVAK W: Cyclosporine-induced neurotoxicity during treatment of Crohn's disease: lack of correlation with previously reported risk factors. Am. J. Gastroenterol. (2001) 96:2778-2782.
33. BAUMGART DC, WIEDENMANN B, DIGNASS AU: Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment. Pharmacol. Ther. (2003) 17:1273-1281.
34. BOUSVAROS A, KIRSCHNER BS, WERLIN SL et al.: Oral tacrolimus treatment of severe colitis in children. J. Pediatr. (2000) 137:794-799.
35. CUMMINGS JR, HERRLINGER KR, TRAVIS SP, GORARD DA, MCINTYRE AS, JEWELL DP: Oral methotrexate in ulcerative colitis. Aliment. Pharmacol. Ther. (2005) 21:385-389.
36. CAMPBELL MS, REDDY KR: Review article: the evolving role of liver biopsy. Aliment. Pharmacol. Ther. (2004) 20:249-259.
37. SHEN C, MAERTEN P, GEBOES K, VAN ASSCHE G, RUTGEERTS P, CEUPPENS JL: Infliximab induces apoptosis of monocytes and T lymphocytes in a human-mouse chimeric model. Clin. Immunol (2005) 115:250-259.
38. HANAUER SB, FEAGAN BG, LICHTENSTEIN GR et al.: Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet (2002) 59:1541-1549.
39. RUTGEERTS P, SANDBORN WJ, FEAGAN BG et al.: Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. (2005) 353:2462-2476.
40. JARNEROT G, HERTERVIG E, FRIIS-LIVY I et al.: Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology (2005) 128:1805-1811.
41. MAMULA P, MARKOWITZ JE, COHEN LJ, VON ALLMEN D, BALDASSANO RN: Infliximab in pediatric ulcerative colitis: two-year follow-up. J. Pediatr. Gastroenterol. Nutr. (2004) 38:298-301.
42. EIDELWEIN AP, CUFFARI C, ABADOM V, OLIVA-HEMKER M: Infliximab efficacy in pediatric ulcerative colitis. Inflamm. Bowel Dis. (2005) 11:213-218.
43. CHEIFETZ A, SMEDLEY M, MARTIN S et al.: The incidence and management of infusion reactions to infliximab: a large center experience. Am. J. Gastroenterol. (2003) 98:1315-1324.
44. JACOBSTEIN DA, MARKOWITZ JE, KIRSCHNER BS et al.: Premeditation and infusion reactions with infliximab: results from a pediatric inflammatory bowel disease consortium. Inflamm. Bowel Dis. (2005) 11:442-446.
45. RIEGERT-JOHNSON DL, GODFREY JA, MYERS JL, HUBMAYR RD, SANDBORN WJ, LOFTUS EV Jr: Delayed hypersensitivity reaction and acute respiratory distress syndrome following infliximab infusion. Inflamm Bowel Dis. (2002) 8:186-191.
46. VERMIERE S, NOMAN M, VAN ASSCHE G et al.: Automimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology (2003) 125:32-39.
47. BRATCHER JM, KORELITZ BI: Toxicity of infliximab in the course of treatment of Crohn's disease. Expert Opin. Drug Saf. (2006) 5:9-16.
48. BOYER JF, JAMARD B, EL MAHOUS et al.: New onset acute heart failure and ventricular tachycardia after therapy with a tumor necrosis factor antagonist. Clin. Exp. Rheumatol. (2005) 23:274-275.
49. FRIESEN CA, CALABROC, CHRISTENSON K et al.: Safety of infliximab treatment in pediatric patients with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. (2004) 39:265-269.
50. DIMAAKOU K, PAPAIOANNIDES D, LATSI P, KATSIMBOULA S, KORANTZOPOULOS P, ORPAHNIDOU D: Disseminated tuberculosis complicating anti-TNF-alpha treatment. Int. J. Clin. Prac. (2004) 58:1052-1055.
51. WOLFE F, MICHAUD K: Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. (2004) 50:1740-1751.
52. THAYU M, MARKOWITZ JE, MAMULA P, RUSSO PA, MUINOS WI, BALDASSAN0 RN: Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J. Pediatr. Gastroenterol. Nutr. (2005) 40:220-222.
53. FARRELL RG, ALSAHLI M, JEEN YT et al.: Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology (2003) 124:917-924.
54. BAERT F, NORMAN M, VERMEIRE S et al.: Influence of immunogenicity on the long term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. (2003) 348:601-608.
55. RUTGEERTS P, FEAGAN BG, LICHTENSTEIN GR et al.: Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology (2004) 126:402-413.
56. SANBORN WJ, YEDNOCK TA: Novel approaches to treating inflammatory bowel disease: targeting alpha-4 integrin. Am. J. Gastroenterol. (2003) 98:2372-2382.
57. SANDBORN WJ, COLOMBEL JF, ENNS R et al.: Natalizumab induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. (2005) 353:1912-1925.
58. HYAMS J, WILSON D, THOMAS A et al.: A Phase II, multicentre, open-label study of the safety, tolerability and effectiveness of natalizumab in adolescents with moderately to severely active Crohn's disease. Presented at The 2nd World Congress of Pediatric Gastroenterology, Hepatology and Nutrition. Paris, France (3-7 July 2004).
59. GORDON FH, HAMILTON MI, DONOGHUE S et al.: A pilot study of treatment of active ulcerative colitis with natalizumab, a humanized monoclonal antibody to alpha-4 integrin. Aliment. Pharmacol. Ther. (2002) 16:699-705.
60. KANDIEL A, FRASER AG, KORELITZ BI, BRENSINGER C, LEWIS JD: Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut (2005) 54:1121-1125.
61. VAN ASSHCE G, VAN RANST M, SCIOT R et al.: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. (2005) 353:362-368.
62. FEAGAN BG, GREENBERG GR, WILD G et al.: Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N. Engl. J. Med. (2005) 352:2499-2507.
63. BARISCH CF: Alicaforsen therapy in inflammatory bowel disease. Expert Opin. Biol. Ther. (2005) 5:387-391.
64. VAN DEVENTER SJ, TAMI JA, WEDEL MK: A randomized, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut (2004) 53:1646-1651.
65. VAN ASSCHEG, RUTGEERTS P: Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease. Am. J. Physiol. Gastrointest. Liver Physiol. (2005) 288:G169-G174.
66. CREED TJ, NORMAN MR, PROBERT CS et al.: Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colits. Aliment. Pharmacol. Ther. (2003) 18:65-67.
67. CREED T, PROBERT C, DAYAN C et al.: Basiliximab (anti-CD25) for the treatment of steroid resistant ulcerative colitis. Gastroenterology (2004) 126:A75.
68. VAN ASSCHE G, DALLE I, NOMAN M et al.: A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am. J. Gastronterol. (2003) 98:369-376.
69. SCHWARZER A, RICCIARDELLI I, KIRKHAM S et al.: Management of fulminating ulcerative colitis in childhood with chimeric anti-CD25 antibody. J. Pediatr. Gastroenterol. Nutr. (2006) 42:245-248.
70. PLEVY S, SALZBERG G, VAN ASSCHE et al.: A humanized anti-CD3 monoclonal antibody, visilizumab, for the treatment of severe steroid refractory ulcerative colitis: results of a Phase I study. Gastroenterology (2004) 126:A579.
71. TARGAN S, SALZBERG B, MAYER L et al.: A Phase I-II: multi-dose levels of visilizumab are well tolerated and produce rapid and sustained improvement in ulcerative colitis patients refractory to treatment with iv steroids (IVSR-UC). Gastroenterology (2005) 128:A493.
72. CARPENTA PA, APPLEBAUM FR, COREY L et al.: A humanized non-FeR binding anti-CD3 antibody, visilizumab, for treatment of steroid refractory acute graft versus host disease. Blood (2002) 99:2712-2719.
73. DOTON I, RACHMILEWITZ D: Probiotics in inflammatory bowel disease: possible mechanisms of action. Curr. Opin. Gastroenterol. (2005) 21:426-430.
74. GUSLANDI M, GIOLLO P, TESTONI PA: A pilot trial of Saccharomyces boulardii in ulcerative colitis: Eur. J. Gastroenterol. Hepatol. (2003) 15:607-698.
75. BIBLIONI R, FEDORAK RN, TANNOCK GW et al.: VSL3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am. J. Gastroenterol. (2005) 100:1539-1546.
76. KATO K, MIZUNO S, UMESAKI Y et al.: Randomized placebo-controlled trial assessing the effect of bifidobacgteria-fermented milk on active ulcerative colitis. Aliment. Pharmacol. Ther. (2004) 20:1133-1141.
77. KRUIS W, FRIC P, POKROTNIEKS J et al.: Maintaining remission of ulcrative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut (2004) 53:1617-1623.
78. GIONCHETTI P, RIZZELLO F, HELWIG U et al.: Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology (2003) 124:1202-1209.
79. SUZUKI A, MITSUYAMA K, KOGA H et al.: Bifidogenic growth stimulator for the treatment of active ulcerative colitis: a pilot study. Nutrition (2006) 22:76-81.
80. FURRIE E, MACFARLANE S, KENNEDY A et al.: Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomized controlled pilot trial. Gut (2005) 54:242-249.
81. BOUSVAROS A, GUANDALINI S, BALDASSANO RN et al.: A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children. Inflamm. Bowel Dis. (2005) 11:833-839.
82. PLAYFORD RJ: Peptides and gastrointestinal mucosal integrity. Gut (1995) 37:595-597.
83. SINHA A, NIGHTINGALE J, WEST KP, BERLANG-ACOSTA J, PALYFORD RJ: Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N. Engl. J. Med (2003) 349:350-357.
84. MIYATA M, KASUGAI K, ISHIKAWA T, KAKUMU S, ONISHI M, MORI T: Rebamipide enemas-new effective treatment for patients with corticosteroid dependent or resistant ulcerative colitis. Dig. Dis. Sci. (2005) 50:S119-123.
85. MAKIYAMA K, TAKESHIMA F, HAMAMOTO T: Efficacy of rebamipide enemas in active distal ulcerative colitis and proctitis: a prospective study report. Dig. Dis. Sci (2005) 50:2323-2329.
86. LUGERING N, KUCHARZIK T, STOLL R et al.: Current concept of the role of monocytes/macrophages in inflammatory bowel disease- balance of proinflammatory and immunosuppressive mediators. Ital. J. Gastroenterol. Hepatol. (1998) 30:338-344.
87. HANAI H, WATANABE F, YAMADA M et al.: Adsorptive granulocyte and monocyte apheresis versus prednisolone in patient with corticosteroid-dependent moderately severe ulcerative colitis. Digestion (2004) 70:36-44.
88. KRUIS W, DIGNASS A, STEINHAGEN-THIESSEN E et al.: Open label trial of granulocyte apheresis suggests therapeutic efficacy in chronically active steroid refractory ulcerative colitis. World J. Gastroenterol. (2005) 11:7001-7006.
89. SAWADA K, KUSUGAMI K, SUZUKI Y et al.: Leukocytaphereis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am. J. Gastroenterol. (2005) 100:1362-1369.
90. SAWADA K, EGASHIRA A, OHNISIHI K, FUKUNAGA K, KUSAKA T, SHIMOYAMA T: Leukocytaphereiss (LCAP) for management of fulminant ulcerative colitis with toxic megacolon. Dig. Dis. Sci. (2005) 50:767-773.
91. MORI Y, YOSHIHARA T, ANDO T et al.: Cytapheresis therapy for ulcerative colitis in three pediatric patients. J. Pediatr. Gastroenterol. Nutr. (2004) 39:485-486.
92. TOMOMASA T, KOBAYASHI A, KANEKO H et al.: Granulocyte adsorptive apheresis for pediatric patients with ulcerative colitis. Dig. Dis. Sci. (2003) 48:750-754.
93. BOSCH T: Therapeutic apheresis - state of the art in the year 2005. Ther. Apher. Dial (2005) 9:459-468.
94. TRAVIS S, YAP L, HAWKEY CJ et al.: RDP58 is a novel and potentially effective oral therapy for ulcerative colitis. Inflamm. Bowel Dis. (2005) 11:713-719.
95. INGRAM JR, RHODES J, EVANS BK, THOMAS GA: Preliminary observations of oral nicotine therapy for inflammatory bowel disease: an open-label Phase I-II study of tolerance. Inflamm. Bowel Dis. (2005) 11:1092-1096.
96. INGRAM JR, THOMAS GA, RHODES J et al.: A randomized trial of nicotine enemas for active ulcerative colitis. Clin. Gastroenterol. Hepatol. (2005) 3:1107-1114.
97. MCGRATH J, MCDONALD JW, MACDONALD JK: Transdermal nicotine for induction of remission in ulcerative colitis (Cochrane Review). In: The Cochrane Library, Issue 4. John Wiley, Chicester, UK (2004).
98. SUMMERS RW, ELLIOTT DE, URBAN JF, THOMPSON RA, WEINSTOCK JV: Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology (2005) 128:825-832.
99. HYAMS JS, DAVIS P, GRANCHER K et al.: Clinical outcomes of ulcerative colitis in children. J. Pediatr. (1996) 129:81-88.